Gedeon Richter Plc. Issues Patient Information for Evra Contraceptive Patch
Gedeon Richter Plc. has released patient information for its Evra contraceptive patch. The product is a combination hormonal contraceptive containing norgelstromin and ethinylestradiol.
Gedeon Richter Plc. has provided patient information for Evra, a contraceptive patch. The product is a combined hormonal contraceptive containing the synthetic progestin norgelstromin and the estrogen ethinylestradiol.
Evra is used for the prevention of pregnancy in women. It works by suppressing ovulation and increasing the viscosity of cervical mucus, which impedes sperm penetration into the uterus. Like other hormonal contraceptives, Evra does not protect against HIV or other sexually transmitted infections.
The information highlights contraindications for Evra use, including allergies to its components, history of blood clots, certain liver diseases, and specific types of cancer. Patients experiencing any of these conditions during Evra therapy are advised to discontinue use and consult a physician.
The patch is intended for women of reproductive age, with confirmed safety and efficacy in women aged 18-49 years. The manufacturer advises patients to discuss potential risks with their doctor before starting treatment and to undergo regular medical check-ups.
The patient information also emphasizes vigilance for symptoms of blood clots, as combined hormonal contraceptives can increase the risk of thrombosis, particularly at the beginning of therapy or after extended breaks.